Get Stock Quote Here AbbVie (ABBV) is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs. It originated in 2013 as a spin-off of Abbott Laboratories. AbbVie developed adalimumab, which is marketed under the trade name Humira, a biopharmaceutical treatment for autoimmune diseases that has exceeded $10 billion in global sales. AbbVie’s portfolio of medicines also includes AndroGel, Creon, Duodopa and Duopa, Kaletra, Lupron, Niaspan, Norvir, Sevoflurane, Synagis, Synthroid, TriCor and Trilipix, Viekira, and Zemplar.
Reported before open today (4/28/16) Earnings: EPS $1.15 Revenue $5.96B Estimates: EPS $1.13 Revenue $5.91B
Analyst Upgrade/Downgrade Update Brokerage firm: Leerink Partners Change: Coverage Initiated Previous Rating: N/A Current Rating: Market Perform Previous Price Target: N/A Current Price Target: $70
David Seaburg Is Bullish On AbbVie He said the company has an interesting cancer pipeline, which could provide a boost for the stock. He added that AbbVie has a 4 percent dividend yield and it trades at a discount at 14 times earnings. With positive news about the pipeline AbbVie could trade to $80, believes Seaburg.
AbbVie stock slammed after disappointing results for cancer drug acquired in $5.8 billion deal Source: https://www.marketwatch.com/story/a...22?link=MW_widget_latestnews_stockaholics.net Down nearly 13% yesterday
For all you long-term investors, this is a current dividend aristocrat. The weekly chart shows this is sitting at the 200MA, so it may be a good entry point if you plan to hold for a long period of time (like the dividend aristocrats are intended to be held). Currently in a short/mid-term down trend, however. First chart is the weekly, second chart is the daily. Dividend Yield is 5%
ABBV today reaffirming the overall downward trend since early 2018. It'll be worth watching the coming weeks to see if it holds the bottom channel before resuming what I would expect to be continued decent swing-trade opportunities.
Dividend Stock Spotlight: AbbVie (ABBV) Mon, Nov 11, 2019 The Health Care sector has rebounded recently, and pharmaceutical stock AbbVie (ABBV) has rallied right alongside the sector. Since reaching its multi-year low around $62 in the middle of August, which also coincided with support from the top end of its former trading range, ABBV has surged over 37%. While it is currently pretty extended at over 2 standard deviations above its 50-DMA, the rally has broken what had been an 18-month downtrend from early 2018. One factor that weighed on the stock during that time was concerns over generic competition as the patent for the company's arthritis drug Humira—which makes up the bulk of the company's revenues—is set to expire in 2023. Despite that looming headwind, ABBV has made efforts to diversify its revenue sources including on-going discussions for the acquisition of Botox maker Allergan (AGN). Additionally, other product lines are experiencing considerable growth such as its cancer treatment Imbruvica which saw revenues over $1.25 billion in the most recent quarter; a 29.3% YoY growth rate. Even with the massive surge, ABBV is still the highest yielding stock in the S&P 500 Health Care sector. Yielding 5.54%, the next highest dividend in the sector is Pfizer (PFE) which yields 3.9%. That dividend is more than twice the size of the average S&P 500 and Health Care sector stock. Earlier this month, the company announced that the quarterly payout would be raised another 10%. Given that the payout ratio now sits at 84.1%, the ratio is getting a bit high, but the company's long dividend history makes this an easier pill to swallow. ABBV has now raised its dividend for 48 consecutive years (includes when the stock was part of Abbott Labs (ABT) from which it was spun off in 2013), making it a Dividend Aristocrat. Not only does ABBV belong to this group, but it also boasts the highest yield of all the aristocrats. For reference, ABBV's stock goes Ex-Dividend on January 14th, 2020.
I have a little cash now! I got rid of CVS yesterday cause it wasn't doing anything for me. I got a whole $3.46 capital gain from them.